Literature DB >> 28167612

JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy.

Aurelien Marabelle1,2, Sandrine Aspeslagh1, Sophie Postel-Vinay1,3, Jean-Charles Soria4,3.   

Abstract

JAK mutations could be one of the primary escape mechanisms to anti-PD-1/PD-L1 immunotherapy via impaired IFNγ signaling in cancer cells and could be used to identify patients unlikely to benefit from these treatments. Cancer Discov; 7(2); 128-30. ©2017 AACR.See related article by Shin et al., p. 188. ©2017 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28167612     DOI： 10.1158/2159-8290.CD-16-1439

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  10 in total

Review 1.  TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis.

Authors:  Xiaohang Liu; Wei Wu; Ligang Fang; Yingxian Liu; Wei Chen
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

Review 2.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.

Authors:  Daniela Bruni; Helen K Angell; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2020-08-04       Impact factor: 60.716

3.  Development and validation of a genomic mutation signature to predict response to PD-1 inhibitors in non-squamous NSCLC: a multicohort study

Authors:  Xue Bai; De-Hua Wu; Si-Cong Ma; Jian Wang; Xin-Ran Tang; Shuai Kang; Qiang John Fu; Chuan-Hui Cao; He-San Luo; Yu-Han Chen; Hong-Bo Zhu; Hong-Hong Yan; Yi-Long Wu; Zhong-Yi Dong
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751

4.  Status of programmed death-ligand 1 expression in sarcomas.

Authors:  Hyung Kyu Park; Mingi Kim; Minjung Sung; Seung Eun Lee; Yu Jin Kim; Yoon-La Choi
Journal:  J Transl Med       Date:  2018-11-06       Impact factor: 5.531

5.  Enhanced mitochondrial pyruvate transport elicits a robust ROS production to sensitize the antitumor efficacy of interferon-γ in colon cancer.

Authors:  YunYan Tai; Fengjun Cao; Mingxing Li; Pindong Li; Tao Xu; Xuanbin Wang; Yuandong Yu; Bing Gu; Xiongjie Yu; Xiaojun Cai; Feng Ao; Peng Ge; Longchao Xiang; Bingbing Yang; Yingpin Jiang; Yong Li
Journal:  Redox Biol       Date:  2018-11-03       Impact factor: 11.799

6.  Molecular and genomic characterisation of a panel of human anal cancer cell lines.

Authors:  Alexander G Heriot; Robert G Ramsay; Wayne A Phillips; Glen R Guerra; Joseph C Kong; Rosemary M Millen; Matthew Read; David S Liu; Sara Roth; Shienny Sampurno; Joseph Sia; Maria-Pia Bernardi; Timothy J Chittleborough; Corina C Behrenbruch; Jiasian Teh; Huiling Xu; Nicole M Haynes; Jiaan Yu; Richard Lupat; David Hawkes; Natasha Di Costanzo; Richard W Tothill; Catherine Mitchell; Samuel Y Ngan
Journal:  Cell Death Dis       Date:  2021-10-18       Impact factor: 8.469

7.  B2M and JAK1/2-mutated MSI-H Colorectal Carcinomas Can Benefit From Anti-PD-1 Therapy.

Authors:  Chenzhi Zhang; Dandan Li; Binyi Xiao; Chi Zhou; Wu Jiang; Jinghua Tang; Yuan Li; Rongxin Zhang; Kai Han; Zhenlin Hou; Linjie Zhang; Qiaoqi Sui; Leen Liao; Zhizhong Pan; Xiaoshi Zhang; Peirong Ding
Journal:  J Immunother       Date:  2022-05-01       Impact factor: 4.456

8.  The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma.

Authors:  Armand Bensussan; Anne Marie-Cardine; Marie-Léa Gauci; Jérôme Giustiniani; Clémence Lepelletier; Christian Garbar; Nicolas Thonnart; Nicolas Dumaz; Arnaud Foussat; Céleste Lebbé
Journal:  Cancer Immunol Immunother       Date:  2022-04-15       Impact factor: 6.630

9.  Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.

Authors:  Ajay Major; Justin Kline; Theodore G Karrison; Paul A S Fishkin; Amy S Kimball; Adam M Petrich; Sreenivasa Nattam; Krishna Rao; Bethany G Sleckman; Kenneth Cohen; Koen van Besien; Aaron P Rapoport; Sonali M Smith
Journal:  Haematologica       Date:  2022-07-01       Impact factor: 11.047

10.  Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer.

Authors:  Young Kwang Chae; Wooyoung M Choi; William H Bae; Jonathan Anker; Andrew A Davis; Sarita Agte; Wade T Iams; Marcelo Cruz; Maria Matsangou; Francis J Giles
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.